￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

News

Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Analysis of the efficacy of ceritinib in the treatment of ALK-positive lung cancer

2025-10-19 11:44:20

Check Details
The third-generation targeted drug lorlatinib has remarkable therapeutic effects for lung cancer!

2025-10-19 11:44:20

Check Details
How should patients with lung cancer use ceritinib correctly?

2025-10-19 11:44:20

Check Details
Has the lung cancer drug lorlatinib been approved for marketing in China?

2025-10-19 11:44:20

Check Details
Medical insurance reimbursement ratio of ALK lung cancer targeted drug ceritinib in 2021

2025-10-19 11:44:20

Check Details
The third-generation targeted drug for lung cancer, lorlatinib, can significantly improve the survival of patients with ALK-positive non-small cell lung cancer_ Kanghule

2025-10-19 11:44:20

Check Details
How much does a box of lung cancer targeted drug lorlatinib cost? Where to buy it?

2025-10-19 11:44:20

Check Details
What should I do if my lung cancer becomes resistant to lorlatinib?

2025-10-19 11:44:20

Check Details
How long can patients with advanced lung cancer live after taking lorlatinib?

2025-10-19 11:44:20

Check Details
The effect of vandetanib in the treatment of lung cancer patients with specific gene mutations

2025-10-19 11:44:20

Check Details
Third-generation ALK inhibitor for lung cancer: lorlatinib

2025-10-19 11:44:20

Check Details
Special lung cancer targeting drug vandetanib

2025-10-19 11:44:20

Check Details
Category
相关知识